NCT01135186

Impact of KUVAN® on Gastric Relaxation in Women With Diabetic Gastroparesis.

Kuvan® (Sapropterin Dihydrochloride) for Improving Gastric Accommodation in Women With Diabetic Gastroparesis (KIGA-DG)

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 9 (actual)
• Sponsor: Stanford University · Academic / Other
• Sex: Female
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Kuvan® (sapropterin dihydrochloride) for Improving Gastric Accommodation in Women with Diabetic Gastroparesis (KIGA-DG)

Detailed description

Patients are invited to participate in a research study of Kuvan® (sapropterin dihydrochloride). We hope to learn whether treatment with Kuvan® is safe and effective in improving the ability of the stomach to relax after eating and improving the symptoms of diabetic gastroparesis. Women are selected as a possible participant in this study because they have diabetes and moderate to severe gastroparesis (meaning stomach empties slowly).

Conditions

• Gastroparesis

Interventions

Type	Name	Description
DRUG	sapropterin dihydrochloride	sapropterin dihydrochloride: 10mg/kg/day

Timeline

• Start date: 2010-05-01
• Primary completion: 2012-11-01
• Completion: 2012-11-01
• First posted: 2010-06-02
• Last updated: 2019-09-10
• Results posted: 2017-03-29

Locations

1 site across 1 country: United States